

comorbidity (AD+D group) (age 41.2 (SD 9.903), 22% females) and 112 healthy controls (age 35.5 (SD 8.286), 15% females). rs1108580 and rs1611115 were detected by RT-PCR.

Results: For rs161111580, frequencies of minor T allele ($p=0.031$) and TT genotype ($p=0.017$) was higher, CC genotype ($p=0.042$) was lower in AD group vs. controls. rs161111580 T allele and TT genotype increases the risk of AD (OR=3.715, 95%CI [1.728-7.986], $P=0.001$ and OR=4.009, 95%CI [1.502-10.699], $P=0.006$). For rs161111580, frequency of TT genotype ($p=0.009$) was higher in AD+D group vs. controls. For rs1108580, frequency of major A allele ($p=0.059$, trend) was higher in AD+D, then in AD group. Major A allele rs1108580 increases the risk of depression in alcohol-dependent patients (OR=2.74, 95%CI [1.283-5.855], $P=0.001$).

Conclusions: It was shown that the DBH rs1108580 increases the risk of depression in patients with alcohol dependence.

Disclosure: No significant relationships.

Keywords: Alcohol dependence; Dopamine; Genetics; Depression

EPP0501

Symptoms of diabetes distress, depression, and anxiety in people with type 2 diabetes: identifying central and bridge symptoms using network analysis

A. Mcinerney^{1*}, N. Lindekilde², A. Nouwen³, N. Schmitz⁴ and S. Deschenes¹

¹University College Dublin, Psychology, Dublin, Ireland; ²University of Southern Denmark, Psychology, Odense, Denmark; ³Middlesex University, Psychology, London, United Kingdom and ⁴University of Tübingen, Medicine, Tübingen, Germany

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.736

Introduction: People with diabetes are vulnerable to diabetes-related distress and are more likely to experience depressive and anxiety symptoms than the general population. Diabetes distress, depressive, and anxiety symptoms also tend to commonly co-occur.

Objectives: This study aimed to apply network analysis to explore the associations between diabetes distress, depressive, and anxiety symptoms in a cohort of adults with type 2 diabetes.

Methods: Data were from the baseline (2011) assessment of the Evaluation of Diabetes Insulin Treatment (EDIT) study ($N=1,796$; 49% female; mean age = 60, $SD=8$) from Quebec, Canada. A first network using the 17 items of the diabetes distress scale (DDS-17) was estimated. A second network was estimated using the 17 items of the DDS-17, the 9 depressive items of the PHQ-9, and the 7 anxiety items of the GAD-7. Symptom centrality, network stability, and bridge symptoms were examined.

Results: Regimen-related and physician-related distress symptoms were amongst the most central (highly connected) in the diabetes distress network. *Worrying too much* (anxiety), *Not feeling motivated to keep up diabetes self-management* (diabetes distress), and *Feeling like a failure* (depression) were the most central symptoms in the combined network. *Feeling like a failure* (depression) was highly connected to diabetes distress symptoms, representing a potential bridge between diabetes distress and depression.

Conclusions: Identifying central and bridge symptoms may provide new insights into diabetes distress, depressive, and anxiety symptom maintenance and comorbidity in people with type 2 diabetes.

Disclosure: No significant relationships.

Keywords: Network Analysis; comorbidity; diabetes; diabetes-distress

EPP0502

Evaluation of the role of lisdexamfetamine on attention-deficit/hyperactivity disorder common psychiatric comorbidities: mechanistic insights on binge eating disorder and depression

J.R. Gutiérrez Casares^{1*}, J. Quintero², P. Rodríguez³, C. Montoto³, T. Pozo-Rubio³, C. Segú-Vergés⁴ and M. Coma⁵

¹Hospital Perpetuo Socorro, Unidad Ambulatoria De Psiquiatría Y Salud Mental De La Infancia, Niñez Y Adolescencia, Badajoz, Spain; ²Hospital Universitario Infanta Leonor. Universidad Complutense., Servicio De Psiquiatría, Madrid, Spain; ³Takeda Farmacéutica España, Medical Department, Madrid, Spain; ⁴Anaxomics Biotech, Molecular Health Department, Barcelona, Spain and ⁵Anaxomics SL, Molecular Physiology, Barcelona, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.737

Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a psychiatric condition in which children suffer from inattentiveness, hyperactivity, and or impulsivity. ADHD patients frequently present comorbid psychiatric disorders: in adults, the most common are depression, substance-related disorders, anxiety, and eating disorders. Children and adolescents present conduct disorders, learning disorders, anxiety and depression. Since ADHD and its psychiatric comorbidities share similarities, a partial overlap of their pathophysiological mechanisms has been suggested. ADHD, can be treated with lisdexamfetamine (LDX), a prodrug indicated by the FDA as treatment for binge eating disorder (BED) and ADHD.

Objectives: To evaluate, through a systems biology-based *in silico* method, the efficacy of LDX as first-line ADHD treatment to improve ADHD psychiatric comorbidities. Furthermore, we explored the molecular mechanisms behind LDX's action.

Methods: We used the systems biology- and artificial intelligence-based Therapeutic Performance Mapping System (TPMS) technology to characterise and model ADHD comorbidities. Artificial neural networks (ANNs) algorithms were used to identify specific relationships between protein sets. Finally, we modelled the mechanisms of LDX for the most relevant comorbidities by using sampling methods and comorbidity-specific virtual patients in each case.

Results: This study predicts a strong relationship between LDX's targets and proteins involved in BED and depression (Fig 1). Our results could be explained not only by LDX role in neurotransmitter regulation, but also by modulation of neuroplasticity (BDNF/NTRK2, GSK3), neuroinflammation (interleukins, inflammasome), oxidative stress (NOS2, SOD), and the hypothalamic-pituitary-adrenal (HPA) axis (CRH, CRHR1).

Figure 1. Artificial neural network evaluation of the impact of lisdexamfetamine over comorbidities.

	Depression	Anxiety	Bipolar disorder	Binge eating disorder	Tic disorder
LDX	Very high (94%)	Medium (76%)	Low (17%)	Very high (94%)	Medium (71%)

Categories: Very high (score 100-92, p-value <0.01); High (score 92-77, p-value <0.05); Medium (score 77-37, p-value <0.25); Low (score <37, p-value ≥0.25).

Conclusions: These findings could be used in pre-clinical and clinical future investigations to assess optimal treatment for ADHD patients with psychiatric comorbidities.

Disclosure: JRGC: speaker for Takeda and Shire, research funding from Shire and Lumbeck, collaborations with Laboratoires Servier JQ: speaker or scientific advisor for Takeda, Janssen, Rubio. Investigation funding: Instituto de Salud Carlos III. PR, CM, TPR: full-ti
Keywords: Artificial intelligence; lisdexamfetamine; attention-deficit/hyperactivity disorder; Psychiatric comorbidities

EPP0504

Radiation-associated cerebrophthalmic effects

K. Loganovsky^{1*}, P. Fedirko², D. Marazziti³, T. Loganovskaja¹, K. Kuts¹, I. Perchuk¹, T. Babenko², K. Antypchuk¹ and G. Kreinis¹

¹State Institution “National Research Centre for Radiation Medicine of National Academy of Medical Sciences of Ukraine”, Radiation Psychoneurology, Institute Of Clinical Radiology, Kyiv, Ukraine; ²State Institution “National Research Centre for Radiation Medicine of National Academy of Medical Sciences of Ukraine”, Institute Of Radiation Hygiene And Epidemiology, Kyiv, Ukraine and ³University of Pisa, Clinical And Experimental Medicine, Section Of Psychiatry, Pisa, Italy

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.738

Introduction: We proposed to consider the brain and eye as a target of ionizing radiation exposure. Prevention of potential radiation-associated cerebrophthalmic effects are crucial for successful long-term space missions; interventional radiology; medical, occupational and accidental irradiation

Objectives: Determination of radiation-associated cerebrophthalmic effects in the long term after irradiation in adulthood and *in utero*.

Methods: Neuropsychiatric, ophthalmological, neurophysiological and neuropsychological assessment of irradiated in adulthood (57 Chernobyl accident clean-up workers, liquidators), 52 persons exposed *in utero* as a result of the Chernobyl accident, comparison group (51 combatants of the Antiterrorist operation in Donbass), and 53 healthy people.

Results: Radiation-associated cerebrophthalmic pathology is characterized by high neuropsychiatric and ophthalmic comorbidity, which increases in proportion to the radiation dose, and is mainly represented by chronic vascular and degenerative diseases of the brain and retina, mild cognitive impairment (after irradiation in adulthood), as well as disorders of the autonomic nervous system; non-psychotic organic mental disorders; neurotic, stress-related and somatoform disorders; vascular and dystrophic processes in the retina (after *in utero* exposure). Characteristic of both

radiological scenarios remains intellectual disharmony due to a decrease in the verbal IQ. The delay and attenuation of cerebral visual afferentation processing were observed in prenatally exposed.

Conclusions: Radiation-associated cerebrophthalmic effects in the long term after irradiation in adulthood and *in utero* could be mainly classified as a “small vessel disease of the brain and eye” of vascular-degenerative nature and possible latent demyelination after irradiation *in utero*.

Disclosure: No significant relationships.

Keywords: Chernobyl accident; comorbidity; Ionizing radiation; cerebrophthalmic effects

EPP0505

Mental health evaluation of patients with Inflammatory Bowel Disease and psychiatric comorbidities during the COVID-19 pandemic

S. Vanzetto^{1*}, M. Vismara^{1,2}, A. Frediani¹, N. Cassina¹, G. Maconi³, M. Bosi¹, C. Viganò¹ and B. Dell’Osso^{1,2,4,5}

¹Luigi Sacco University Hospital, Psychiatry 2 Unit, ASST FBF-Sacco, University Of Milan, Milan, Italy; ²“Aldo Ravelli” Center for Nanotechnology and Neurostimulation”, University Of Milan, Milan, Italy; ³Gastroenterology Unit, Department of Biomedical and Clinical Sciences, “I. Sacco” Hospital, Milan, Italy; ⁴Department of Psychiatry and Behavioral Sciences, Stanford University, Milan, Italy and ⁵“Centro per lo studio dei meccanismi molecolari alla base delle patologie neuropsico-geriatriche”, University Of Milan, Milan, Italy

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.739

Introduction: The mental health of subjects with chronic medical illnesses, such as Inflammatory Bowel Disease (IBD- Crohn’s Disease and Ulcerative Colitis), is typically compromised and the current COVID-19 pandemic might have additionally increased this burden.

Objectives: The aim of the present study was to investigate, during the COVID-19 pandemic, if the presence of a comorbid psychiatric disorder has played a role as an aggravating factor on mental health in patients with IBD.

Methods: Twenty Five patients with psychiatric comorbidities (PC+) and twenty five without (PC-) comparable for age and gender, were recruited at the Gastroenterology department at Sacco University Hospital in Milan. Participants were assessed a psychiatric evaluation, collecting socio-demographic variables and measures of anxiety and depression [on the Hospital Anxiety Depression Scale (HADS)], sleep patterns [on the Insomnia Severity Index (ISI)] and general health status [on the Short Form Health Survey 36 (SF-36)].

Comparative statistical analyses were performed with t test with Bonferroni correction.

Results: PC+ (n=25) showed more severe anxiety and depressive symptoms compared with PC- (n=25) (p <.001) and worse sleep pattern (p<.05). With respect to general health status, PC+ showed reduced physical activities (p<.05), social activities (p<.05), mental health (p<.01) and role limitations due to physical health (p<.05).